LAG-3 expression has been demonstrated to be associated with reduced OS and DFS in hepatocellular carcinoma and in Epstein–Barr-virus-positive and MLH1-defective gastric cancer [34,35]. The gene discussed is LAG3; the disease is hepatocellular carcinoma.